



(11)

EP 1 504 035 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 74

(51) Int Cl.:
C07K 16/28 ^(2006.01) **C12N 15/13** ^(2006.01)
C12N 15/85 ^(2006.01) **C12N 5/10** ^(2006.01)
A61K 39/395 ^(2006.01) **A61K 31/7088** ^(2006.01)
A61P 35/00 ^(2006.01)

(48) Corrigendum issued on:
28.02.2018 Bulletin 2018/09

(86) International application number:
PCT/GB2003/001934

(45) Date of publication and mention
of the grant of the patent:
31.03.2010 Bulletin 2010/13
20.12.2017 Bulletin 2017/51

(87) International publication number:
WO 2003/093320 (13.11.2003 Gazette 2003/46)

(21) Application number: **03718974.3**

(22) Date of filing: **02.05.2003**

(54) **ANTIBODIES SPECIFIC FOR HUMAN CD22 AND THEIR THERAPEUTIC AND DIAGNOSTIC USES**

ANTIKÖRPER GEGEN HUMANES CD22 UND DEREN THERAPEUTISCHE UND DIAGNOSTISCHE
VERWENDUNGEN

ANTICORPS SPECIFIQUES A L' HUMAIN CD22 ET LEURS UTILISATION THERAPEUTIQUES ET
DIAGNOSTIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR
Designated Extension States:
AL LT LV MK

(74) Representative: **Mercer, Christopher Paul et al**
Carpmaels & Ransford LLP
One Southampton Row
London
WC1B 5HA (GB)

(30) Priority: **02.05.2002 GB 0210121**

(56) References cited:
WO-A-00/31141 WO-A-00/74718
WO-A-01/94585 WO-A-91/09967
WO-A-92/15683 WO-A-94/29451
WO-A-96/04925 WO-A-98/19704
US-A- 5 714 350

(43) Date of publication of application:
09.02.2005 Bulletin 2005/06

(73) Proprietor: **UCB Pharma, S.A.**
1070 Brussels (BE)

(72) Inventors:
• **POPPLEWELL, Andrew George**
Slough,
Berkshire SL1 3WE (GB)
• **TICKLE, Simon Peter**
Slough,
Berkshire SL1 3WE (GB)
• **LADYMAN, Heather Margaret**
Slough,
Berkshire SL1 3WE (GB)

• **S. LEUNG ET AL.: "Construction and
characterization of a humanized, internalizing,
B-cell (CD22)-specific, leukemia/lymphoma
antibody, LL2." MOLECULAR IMMUNOLOGY,**
vol. 32, no. 17/18, December 1995 (1995-12),
pages 1413-1427, XP000942678 Oxford, GB

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 504 035 B8

- S. LEUNG ET AL.: "Effect of Vk framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site." INTERNATIONAL JOURNAL OF CANCER, vol. 60, 1995, pages 534-538, XP002066554 New York, NY, USA
- I. BENHAR ET AL.: "Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization." BIOCONJUGATE CHEMISTRY, vol. 5, July 1994 (1994-07), pages 321-326, XP000564453 Washington, DC, USA
- T. VAUGHAN ET AL.: "Human antibodies by design." NATURE BIOTECHNOLOGY, vol. 16, June 1998 (1998-06), pages 535-539, XP000941675 New York, NY, USA cited in the application
- J. CARNAHAN ET AL.: "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties." CLINICAL CANCER RESEARCH, vol. 9, no. suppl., 1 September 2003 (2003-09-01), pages 3982S-3990S,
- J. DIJOSEPH ET AL.: "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22." CANCER IMMUNOLOGY & IMMUNOTHERAPY, vol. 54, 2005, pages 11-24,
- J. DIJOSEPH ET AL.: "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies." BLOOD, vol. 103, no. 5, 1 March 2004 (2004-03-01), pages 1807-1814,
- S. VAN ROSSENBERG ET AL.: "A structure-function study of ligand recognition by CD22beta." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 16, 20 April 2001 (2001-04-20), pages 12967-12973, U.S.A.
- J. BROWNING: "B cells move to centre stage: Novel opportunities for autoimmune disease treatment." NATURE REVIEWS DRUG DISCOVERY, vol. 5, no. 7, July 2006 (2006-07), pages 564-576,